UroGen Pharma Ltd. URGN

We need more volume

xplore
URGN Analyst Ratings
ANALYST ACTION RATING NOW PT PRIOR PT NOW LAST UPDATED
HC Wainwright & Co. Maintains Buy $23 $54 8/1/2023
Goldman Sachs Maintains Neutral $11 $18 7/31/2023
HC Wainwright & Co. Reiterates Buy N/A $23 6/21/2023
Oppenheimer Reiterates Outperform N/A $22 5/15/2023
HC Wainwright & Co. Reiterates Buy N/A $23 5/15/2023
HC Wainwright & Co. Reiterates Buy N/A $

02/08/2023 05:00PM ET
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Conference Call and Webcast Scheduled for Thursday, August 10, 2023 at 10:00 AM ET

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2023 financial results on Thursday, August 10, 2023, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product Jelmyto® (mitomycin) for pyelocaliceal solution, and investigational treatment UGN-102

$URGN Manipulate action!!!!!